13 — HUTCHMED (China) Share News
0.000.00%
Last trade - 00:00- HK$25.22bn
- HK$19.05bn
- $838.00m
- 79
- 20
- 41
- 42
RCS - Hutchmed China Ltd - Data to be Presented at AACR Congress 2024
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED and Innovent Announce NDA Acceptance
AnnouncementRCS - Hutchmed China Ltd - Savolitinib sNDA Accepted in China
AnnouncementRCS - Hutchmed China Ltd - Initiation of Registration Stage of P2/3 Trial
AnnouncementREG - Hutchmed China Ltd - LTIP and Share Option Scheme
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under the LTIP
AnnouncementRCS - Hutchmed China Ltd - Publication of Form 20-F
AnnouncementREG - Hutchmed China Ltd - 2023 Full Year Results and Business Updates
AnnouncementRCS - Hutchmed China Ltd - Presentation of Phase III Data on Fruquintinib
AnnouncementRCS - Hutchmed China Ltd - Inmagene Exercises Option for Two Drug Candidates
AnnouncementREG - Hutchmed China Ltd - HUTCHMED to Announce 2023 Final Results
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Receives Marketing Approval in Hong Kong
AnnouncementRCS - Hutchmed China Ltd - Sovleplenib NDA Granted Priority Review in China
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementREG - Hutchmed China Ltd - Blocklisting Six Monthly Return
AnnouncementREG - Hutchmed China Ltd - Overseas Regulatory Announcement
AnnouncementRCS - Hutchmed China Ltd - Completed Enrollment of Phase II/III Trial
AnnouncementRCS - Hutchmed China Ltd - Inclusion in National Reimbursement Drug List
AnnouncementREG - Hutchmed China Ltd - Overseas Regulatory Announcement
Announcement